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Artificial electronic pacemakers have been 
successfully driving the hearts and reliably saving the 
lives of millions by providing cardiac pacing for a variety 
of cardiac bradyarrhythmias. However, there are several 
caveats to this technology not merely limited to 
procedural and hardware complications associated with 
its usage. These hurdles have prompted research in the 
development of a biological counterpart which could 
replace or supplement its electronic version. The concept 
of the biological pacemaker is very appealing, albeit most 
challenging. If normal working myocytes or conduction 
system cells could be transformed to perform the 
pacemaker function, there would be no need to replace 
pulse generator, and no issues with circuit or lead failure, 
size mismatch or foreign body infection would ever arise. 
Two general approaches have been pursued in the 
development of biological pacemakers, gene transfer into 
cardiac myocytes to create or enhance the pacemaker 
function, and cell transplantation into the heart that can 
perform the pacemaker function on their own or in 
conjunction with native cardiac myocytes. 1,2 There are 
always pros and cons of these different approaches. 
Importantly, in order to develop such a biologic 
pacemaker, two elements are deemed essential: to select a 
gene that can direct cells of non-automatic tissue to 
induce spontaneous phase 4 depolarization in a reliable 
and automatic manner, similar to the native sinus node 
cells or other conduction tissue with inherent 
automaticity; and subsequently to develop a technique to 
deliver this gene into the target tissue. Gene transfer 
methods may use injection of adenoviral vectors, of 
genetically engineered stem cells or use of gene-carrying 
mesenchymal stem cells. 1 Thus, biologic pacing could be 
accomplished either by genetic engineering, cellular 
therapy or a combination of both. Over the past decade, 
gene therapy has been explored to upregulate β2-
adrenergic receptors, to downregulate inward rectifier 
current, and to overexpress pacemaker current as 
potential sources of biological pacemakers. Cell therapy 
approaches have explored the ‘‘forcing’’ of embryonic 
stem cells to evolve along cardiac pacemaker cell lines 
and the use of adult mesenchymal stem cells as platforms 
for delivery of specific gene therapies.2  
Cardiac ion channels and calcium handling proteins 
forming the key molecular components of the native 
cardiac pacemaker action potential were the primary 
candidates for gene therapy based biological pacemaking. 
Modulation of ion channels and other pacemaking 
associated proteins, either by gene delivery/ cell therapy 
or a combination of both are being intensely and 
thoroughly investigated. Pluripotent/ multipotent stem 
cells serve as excellent vehicles for carrying such genes, 
which have been modified to ensure that the implanted 
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cell transforms into a pacemaker-like cell. Implantation of 
hybrid/ tandem pacemakers could protect against the risk 
associated with the malfunction of either the biological or 
artificial pacemaker in the patient. Some of these gene- 
and cell-based approaches aim at manipulating the basic 
determinants of native pacemaker function in normal 
hearts. Techniques employed to attain these targets 
include gene transfer via viral infection or naked plasmid 
transfection, use of embryonic stem cells that incorporate 
a complement of native genes, or adult mesenchymal 
stem cells engineered as platforms to carry pacemaker 
genes. More recently methods have emerged to reproduce 
pacemaker action potentials in noncardiac cells and/or to 
induce fusion of noncardiac and cardiac cells. The aim 
remains to identify gene(s) which optimize heart rhythm 
avoiding excessive bradycardia or long pauses, but also 
provide a physiological rate response based on metabolic 
and/or catecholamine status.  
Initial attention of biologic pacing has been focused 
on one particular target, the hyperpolarization activated, 
cyclic nucleotide gated (HCN) gene isoforms responsible 
for the funny (If) pacemaker current, which is highly 
expressed in the natural pacemaker, the sinoatrial node, as 
well as in the atrio-ventricular (AV) node and the 
Purkinje fibers of conduction tissue.3 The If current 
controls the rate of spontaneous activity of sinoatrial 
myocytes, hence the heart rate. The reason for which 
investigators of biologic pacing persist in this direction 
relies on the evidence that the If current alone appears to 
be adequate, whether administered via virus or via 
platform, to drive the heart. Initial data indicate that both 
gene and cell therapy approaches can result in effective 
biological pacemaker function over a period of weeks in 
intact animals. Indeed, the use of adult human 
mesenchymal stem cells as a platform for carrying 
pacemaker genes has resulted in the formation of 
functional gap junctions with cardiac myocytes in situ 
leading to propagation of pacemaker current. These 
approaches are encouraging, suggesting that biological 
pacemakers based on this strategy can be brought to 
clinical testing.3,4  The invention of Dr. Rosen and 
colleagues comprises a “nanofilm-encapsulated biological 
pacemaker, composed of a collection of adult human 
mesenchymal stem cells that are modified to mimic the 
natural human pacemaker's ability to generate and 
conduct electrical current, thereby recreating natural 
pacemaker function of the heart”.5 When implanted in the 
myocardium, this platform could potentially stimulate 
impulse initiation and propagation hopefully without any 
adverse effects. With use of adult human mesenchymal 
stem cells as delivery systems, the investigators were able 
to provide a means for administering catecholamine-
responsive biological pacemakers into the left ventricular 
myocardium of adult dogs (afflicted by complete heart 
block and having backup electronic pacemakers) that 
functioned in a stable manner for 6 weeks and manifested 
no cellular or humoral rejection.6  
There is still a long way to go until we have more 
practical and simplified approaches to this novel therapy. 
Only recently, did investigators report the use of venous 
catheters to create a biological pacemaker, using off-the-
shelf clinical equipment in a large animal model (pigs), 
paving the way to direct translational medicine to 
materialize itself.7 They injected an adenoviral vector 
cocktail, expressing dominant-negative inward rectifier 
potassium channel (Kir2.1AAA) and hyperpolarization-
activated cation channel (HCN2) genes, into the AV 
junctional region via a catheter advanced through the 
femoral vein. However, this experiment provided only 
temporary (2 weeks) support and may only be considered 
for cases of pacemaker infection requiring explantation as 
a bridge-to- device pacing for the effective clearance of 
infection prior to the reimplantation of a new electronic 
pacemaker, thus avoiding the indwelling electrocatheter 
needed for temporary pacing.  
However, a potential concern about biological 
pacemakers is the possibility that they might malfunction 
to trigger, depending on the implant site, atrial or 
ventricular tachyarrhythmias. Although no arrhythmic 
activity was reported with use of the HCN family of 
pacemaker channel genes to create biological pacemakers 
when viral vectors or adult human mesenchymal stem 
cells were employed as delivery platforms, nevertheless, 
in preliminary experiments, investigators discovered that 
canine left bundle branch implantation of an adenoviral 
construct of HCN induced ventricular ectopy or 
tachycardia.8,9 However, these If-associated arrhythmias 
could be controlled with If inhibiting drugs such as 
ivabradine, which appeared to suppress ventricular 
tachycardia more readily than sinus rhythm, which might 
confer a therapeutic benefit in such circumstances.9  
Until a tangible and more realistic result has been 
effected, there is a need, at least during clinical trials, to 
implant an electronic alongside with a biological 
pacemaker (tandem pacemaker approach). Of course for 
such an approach to succeed, one has to ensure that the 
dual system is synergistic and remains safe without 
adverse or unpredictable interactions between the 
biological and electronic pacemakers and confers more 
benefit to the patient than would an electronic pacemaker 
alone. There is indeed some preliminary evidence that 
biological pacemakers, like their electronic counterparts, 
can be regulated for basal heart rate and catecholamine 
responsiveness (rate response),10 or might be able to 
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respond to physiological emotional arousal, and increase 
their pacemaker function.11 The concept is to have the 
electronic pacemaker provide a bridge to biological 
pacing therapeutics, until there is more solid evidence for 
the safety and efficacy of this revolutionary novel 
approach.  
Whether the end result of the application of all these 
preliminary data will be a clinically applicable biological 
pacemaker remains to be proven. Although proof of 
concept has been demonstrated, there is still a long way 
to go and many obstacles to overcome before its safe and 
reliable clinical application. First, one needs to identify 
the ideal candidate pacemaker cells, and second to make 
headway in fine-tuning the behavior of these pacemaking 
cells, while finally monitoring and controlling the 
interactions between the pacemaker and host 
myocardium. Thus, there is still need for development of 
new technologies and more testing in the animal 
laboratory to enhance our understanding of mechanisms 
that control gene expression and cell coupling until the 
biological pacemaker becomes a feasible and realistic 
project. Meanwhile, electronic pacemaker systems have 
proven their value, while they are still rapidly evolving 
and for now remain the main and only player in the field.  
As the inventor himself, Dr Michael Rosen,12 has put 
it, in order to “see biological pacemaking in our lifetime”, 
the following are needed: “For virus or stem cell, we need 
evidence that it is superior to the electronic pacemaker in 
terms of adaptability to the body’s physiology and 
duration of effectiveness; evidence regarding long-term 
incidence of inflammation, infection, rejection, neoplasia; 
evidence for/against long-term proarrhythmic potential; 
localization at site of implantation vs migration to other 
sites; other toxicity; optimization of delivery systems”. 
“For stem cell (embryonic, mesenchymal), we need 
evidence regarding persistence of the administered cell 
type vs differentiation into other cell types; in the latter 
event, evidence regarding persistence of pacemaker 
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Although the initial ablation procedure has a modest 
acute success rate (~70%) in patients with atrial 
fibrillation (AF), a repeat procedure adds significant 
improvement (~80%). The short- and mid-term results 
may offer some encouragement, however the longer-term 
results are sobering with arrhythmia-free survival rates 
diving to around 30%. Nevertheless, this disappointing 
rate may increase significantly with a second procedure to 
around 60%. Such data of the long-term results of AF 
ablation are herein reviewed.  
 
 
 
 
 
 
 
 
 
